JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 2
DOI:10.33266/1024-6177-2025-70-2-119-125
V.A. Manukova, I.P. Aslanidis, O.V. Mukhortova,
M.V. Metelkina, I.V. Ekaeva, A.S. Rumyantsev, A.V. Silchenko
11C-Methionine and 18F-Fluorodeoxyglucose PET/CT
in Multiple Myeloma Patients – One-Day Investigation
A.N. Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia
Contact person: V.A. Manukova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Background: To evaluate the impact of PET/СT with 11C-Methionine (MET) and 18F-fluorodeoxyglucose (FDG) on physiological distribution of FDG in patients with multiple myeloma (MM).
Material and methods: 40 patients with a history of MM were included in the analysis, 60 PET/CT exams were conducted: in the 1st group – 20 doubled PET/CT (MET PET/CT followed by FDG PET/CT); in the 2nd group – 20 FDG PET/CT.
Results: Comparative analysis of the physiological accumulation of FDG in two groups of patients with MM – one group passed one day 11C-MET PET/CT followed by 18F-FDG PET/CT and another group passed standard 18F-FDG PET/CT – revealed no statistically significant difference. SULmax and SULmean was calculated in the right lobe of the liver, in the ascending aorta and in the head of the pancreas. The mean values of liver SULmax were: in the first group – 2.37 ± 0.36, in the second group – 2.46 ± 0.40, p = 0.1. The mean values of aortic SULmax were: in the first group – 1.42 ± 0.25, in the second group – 1.51 ± 0.37, p = 0.11. The mean SULmax values in the pancreatic head were: in the first group – 1.43 ± 0.26, in the second group – 1.59 ± 0.36, p = 0.08.
Conclusion: A one-day MET and FDG PET/CT does not affect the pharmacokinetics of FDG and can be used in MM patients.
Keywords: multiple myeloma, PET/CT, 11C-Methionine, 18F-Fluorodeoxyglucose, one-day investigation
For citation: Manukova VA, Aslanidis IP, Mukhortova OV, Metelkina MV, Ekaeva IV, Rumyantsev AS, Silchenko AV. 11C-Methionine and 18F-Fluorodeoxyglucose PET/CT in Multiple Myeloma Patients – One-Day Investigation. Medical Radiology and Radiation Safety. 2025;70(2):119–125. (In Russian). DOI:10.33266/1024-6177-2025-70-2-119-125
References
1. Пурсанова Д.М., Асланиди И.П, Мухортова О.В., Шурупова И.В., Екаева И.В., Трифонова Т.А. ПЭТ/КТ в диагностике инфекционного эндокардита: факторы, влияющие на информативность // Бюллетень НЦССХ им. А.Н.Бакулева РАН. Сердечно-сосудистые заболевания. 2022. Т.23. №S3. С.117 [Pursanova D.M., Aslanidi I.P, Mukhortova O.V., Shurupova I.V., Yekayeva I.V., Trifonova T.A. PET/CT in the Diagnosis of Infective Endocarditis: Factors Affecting the Information Content. Byulleten’ Nauchnogo Tsentra Serdechno-Sosudistoy Khirurgii im. A.N.Bakuleva RAN. Serdechno-Sosudistyye Zabolevaniya = Bulletin of the A.N.Bakulev Scientific Center of Cardiovascular Surgery. Russian Academy of Sciences. Cardiovascular Diseases. 2022;23;S3:117 (In Russ.)].
2. Асланиди И.П., Шурупова И.В., Мухортова О.В., Трифонова Т.А., Пурсанова Д.М., Шавман М.Г. Отдел ядерной диагностики центра им. А.Н.Бакулева: современные достижения и взгляд в будущее // Бюллетень НЦССХ им. А.Н.Бакулева РАН. Сердечно-сосудистые заболевания. 2021. Т.22. №2. С.162-170 [Aslanidi I.P., Shurupova I.V., Mukhortova O.V., Trifonova T.A., Pursanova D.M., Shavman M.G. Department of Nuclear Diagnostics of the A.N. Bakulev Center: Current Achievements and a Look into the Future. Byulleten’ Nauchnogo Tsentra Serdechno-Sosudistoy Khirurgii Im. A.N. Bakuleva RAN. Serdechno-Sosudistyye Zabolevaniya = Bulletin of the A.N.Bakulev Scientific Center of Cardiovascular Surgery. Russian Academy of Sciences. Cardiovascular Diseases. 2021;22;2:162-170 (In Russ.)].
3. Huang J., Chan S.C., Lok V., Zhang L., Lucero-Prisno D.E. 3rd, Xu W., Zheng Z.J., Elcarte E., Withers M., Wong M.C.S. Non-Communicable Disease Global Health Research Group, Association of Pacific Rim Universities. The Epidemiological Landscape of Multiple Myeloma: a Global Cancer Registry Estimate of Disease Burden, Risk Factors, and Temporal Trends. Lancet Haematol. 2022 Sep;9;9:e670-e677. doi: 10.1016/S2352-3026(22)00165-X. Epub 2022 Jul 14. PMID: 35843248.
4. Kwee T.C., Basu S., Saboury B., Ambrosini V., Torigian D.A., Alavi A. A New Dimension of FDG-PET Interpretation: Assessment of Tumor Biology. Eur J Nucl Med Mol Imaging. 2011 Jun;38;6:1158-70. doi: 10.1007/s00259-010-1713-9. Epub 2011 Jan 12. PMID: 21225422.
5. Rasche L., Angtuaco E., McDonald J.E., Buros A., Stein C., Pawlyn C., Thanendrarajan S., Schinke C., Samant R., Yaccoby S., Walker B.A., Epstein J., Zangari M., van Rhee F., Meissner T., Goldschmidt H., Hemminki K., Houlston R., Barlogie B., Davies F.E., Morgan G.J., Weinhold N. Low Expression of Hexokinase-2 is Associated with False-Negative FDG-Positron Emission Tomography in Multiple Myeloma. Blood. 2017 Jul 6;130;1:30-34. doi: 10.1182/blood-2017-03-774422. Epub 2017 Apr 21. PMID: 28432222. PMCID: PMC5501152.
6. Lapa C., Knop S., Schreder M., Rudelius M., Knott M., Jörg G., Samnick S., Herrmann K., Buck A.K., Einsele H., Lückerath K. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement. Theranostics. 2016 Jan 1;6;2:254-61. doi: 10.7150/thno.13921. PMID: 26877783. PMCID: PMC4729773.
7. Okasaki M., Kubota K., Minamimoto R., Miyata Y., Morooka M., Ito K., Ishiwata K., Toyohara J., Inoue T., Hirai R., Hagiwara S., Miwa A. Comparison of (11)C-4’-Thiothymidine, (11)C-Methionine, and (18)F-FDG PET/CT for the Detection of Active Lesions of Multiple Myeloma. Ann Nucl Med. 2015 Apr;29;3:224-32. doi: 10.1007/s12149-014-0931-9. Epub 2014 Nov 25. PMID: 25421383; PMCID: PMC4385147.
8. Isoda A., Kaira K., Iwashina M., Oriuchi N., Tominaga H., Nagamori S., Kanai Y., Oyama T., Asao T., Matsumoto M., Sawamura M. Expression of L-Type Amino Acid Transporter 1 (LAT1) as a Prognostic and Therapeutic Indicator in Multiple Myeloma. Cancer Sci. 2014 Nov;105;11:1496-502. doi: 10.1111/cas.12529. Epub 2014 Oct 9. PMID: 25220100. PMCID: PMC4462375.
9. Filippi L., Frantellizzi V., Bartoletti P., Vincentis G., Schillaci O., Evangelista L. Head-to-Head Comparison between FDG and 11C-Methionine in Multiple Myeloma: A Systematic Review. Diagnostics (Basel). 2023 Jun 9;13;12:2009. doi: 10.3390/diagnostics13122009. PMID: 37370904. PMCID: PMC10296945.
10. Kluge R., Chavdarova L., Hoffmann M., Kobe C., Malkowski B., Montravers F., Kurch L., Georgi T., Dietlein M., Wallace W.H., et al. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin’s Lymphoma. PLoSONE. 2016;11:e0149072. doi: 10.1371/journal.pone.0149072.
11. Siefert J., Kaufmann J., Thiele F., Walter-Rittel T., Rogasch J., Biesen R., Burmester G.R., Amthauer H., Schneider U., Furth C. Performance of Deauville Criteria in [18F]FDG-PET/CT Diagnostics of Giant Cell Arteritis. Diagnostics (Basel). 2023 Jan 3;13;1:157. doi: 10.3390/diagnostics13010157. PMID: 36611449. PMCID: PMC9818714.
12. Lucignani G., Paganelli G., Bombardieri E. The Use of Standardized Uptake Values for Assessing FDG Uptake with PET in Oncology: a Clinical Perspective. Nucl Med Commun. 2004;25:651–656.
13. Sarikaya I., Albatineh A.N., Sarikaya A. Revisiting Weight-Normalized SUV and Lean-Body-Mass-Normalized SUV in PET Studies. J Nucl Med Technol. 2020 Jun;48;2:163-167. doi: 10.2967/jnmt.119.233353. Epub 2019 Oct 11. PMID: 31604893.
14. Riauka T.A., Baracos V.E., Reif R., Juengling F.D., Robinson D.M., Wieler M., McEwan A.J.B. Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PET-A Significant Improvement over Prediction Equations. Front Oncol. 2022 Jul 7;12:812777. doi: 10.3389/fonc.2022.812777. PMID: 35875083. PMCID: PMC9302197.
15. Okasaki M., Kubota K., Minamimoto R., Miyata Y., Morooka M., Ito K., Ishiwata K., Toyohara J., Inoue T., Hirai R., Hagiwara S., Miwa A. Comparison of (11)C-4’-Thiothymidine, (11)C-Methionine, and (18)F-FDG PET/CT for the Detection of Active Lesions of Multiple Myeloma. Ann Nucl Med. 2015 Apr;29;3:224-32. doi: 10.1007/s12149-014-0931-9. Epub 2014 Nov 25. PMID: 25421383. PMCID: PMC4385147.
16. Morales-Lozano M.I., Rodriguez-Otero P., Sancho L., Nuñez-Cordoba J.M., Prieto E., Marcos-Jubilar M., Rosales J.J., Alfonso A., Guillen E.F., San-Miguel J., Garcia-Velloso M.J. 11C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET/CT and Prognostic Value. Int J Mol Sci. 2022 Aug 31;23;17:9895. doi: 10.3390/ijms23179895. PMID: 36077292. PMCID: PMC9456410.
17. Bailly C., Leforestier R., Jamet B., Carlier T., Bourgeois M., Guérard F., Touzeau C., Moreau P., Chérel M., Kraeber-Bodéré F., Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci. 2017 Feb 18;18;2:445. doi: 10.3390/ijms18020445. PMID: 28218709. PMCID: PMC5343979.
18. Jamet B., Bailly C., Carlier T., Touzeau C., Nanni C., Zamagni E., Barré L., Michaud A.V., Chérel M., Moreau P., Bodet-Milin C., Kraeber-Bodéré F. Interest of Pet Imaging in Multiple Myeloma. Front Med (Lausanne). 2019 Apr 9;6:69. doi: 10.3389/fmed.2019.00069. PMID: 31024917. PMCID: PMC6465522.
19. Nakamoto Y., Kurihara K., Nishizawa M., Yamashita K., Nakatani K., Kondo T., Takaori-Kondo A., Togashi K. Clinical Value of 11C-Methionine PET/CT in Patients with Plasma Cell Malignancy: Comparison with 18F-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2013;40:708-715. doi: 10.1007/s00259-012-2333-3.
20. Callander N.S., Baljevic M., Adekola K., Anderson L.D., Campagnaro E., Castillo J.J., Costello C., Devarakonda S., Elsedawy N., Faiman M., Garfall A., Godby K., Hillengass J., Holmberg L., Htut M., Huff C.A., Hultcrantz M., Kang Y., Larson S., Liedtke M., Martin T., Omel J., Sborov D., Shain K., Stockerl-Goldstein K., Weber D., Berardi R.A., Kumar R., Kumar S.K. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022 Jan;20;1:8-19. doi: 10.6004/jnccn.2022.0002. PMID: 34991075.
21. Костина И.Э., Гитис М.К., Менделеева Л.П., Баграмян А.Ю., Соловьев М.В., Грибанова Е.О., Савченко В.Г. Рентгеновская компьютерная томография в диагностике и мониторинге поражения костей при множественной миеломе с использованием низкодозового и стандартного протоколов сканирования // Гематология и трансфузиология. 2018. Т.63. №2. С.113-123 [Kostina I.E., Gitis M.K., Mendeleyeva L.P., Bagramyan A.Yu., Solov’yev M.V., Gribanova Ye.O., Savchenko V.G. X-ray Computed Tomography in the Diagnosis and Monitoring of Bone Lesions in Multiple Myeloma Using Low-Dose and Standard Scanning Protocols. Gematologiya i Transfuziologiya = Hematology and Transfusiology. 2018;63;2:113-123 (In Russ.)]. doi: 10.25837/HAT.2018.13.2.002
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Development of the research concept and design, research methods, collection and analysis of literary material, statistical data processing, writing and scientific editing of the text – V.A. Manukova, I.P. Aslanidi, O.V. Mukhortova, M.V. Metelkina, I.V. Yekaeva, A.S. Rumyantsev, A.V. Silchenko – in equal parts.
Article received: 20.12.2024. Accepted for publication: 25.01.2025.